Inhibition of Soluble Epoxide Hydrolase Ameliorates Phenotype and Cognitive Abilities in a Murine Model of Niemann Pick Type C Disease
Authors:
- Christian Griñán-FerréChristian Griñán-Ferré
- Júlia Companys-AlemanyJCJúlia Companys-Alemany
- Júlia Jarné-FerrerJJJúlia Jarné-Ferrer
- Sandra CodonySCSandra Codony
- Celia González-CastilloCGCelia González-Castillo
- Daniel Ortuño-SahagúnDaniel Ortuño-Sahagún
- Lluïsa VilageliuLVLluïsa Vilageliu
- Daniel GrinbergDGDaniel Grinberg
- Santiago VázquezSantiago Vázquez
- Mercè PallàsMercè Pallàs
Open Access
- 26 March 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (7) , 3409
Abstract
Niemann–Pick type C (NPC) disease is a rare autosomal recessive inherited childhood neurodegenerative disease characterized by the accumulation of cholesterol and glycosphingolipids, involving the autophagy-lysosome system. Inhibition of soluble epoxide hydrolase (sEH), an enzyme that metabolizes epoxy fatty acids (EpFAs) to 12-diols, exerts beneficial effects in modulating inflammation and autophagy, critical features of the NPC disease. This study aims to evaluate the effects of UB-EV-52, an sEH inhibitor (sEHi), in an NPC mouse model (Npc) by administering it for 4 weeks (5 mg/kg/day). Behavioral and cognitive tests (open-field test (OF)), elevated plus maze (EPM), novel object recognition test (NORT) and object location test (OLT) demonstrated that the treatment produced an improvement in short- and long-term memory as well as in spatial memory. Furthermore, UB-EV-52 treatment increased body weight and lifespan by 25% and reduced gene expression of the inflammatory markers (i.e., Il-1β and Mcp1) and enhanced oxidative stress (OS) markers (iNOS and Hmox1) in the treated Npc mice group. As for autophagic markers, surprisingly, we found significantly reduced levels of LC3B-II/LC3B-I ratio and significantly reduced brain protein levels of lysosomal-associated membrane protein-1 (LAMP-1) in treated Npc mice group compared to untreated ones in hippocampal tissue. Lipid profile analysis showed a significant reduction of lipid storage in the liver and some slight changes in homogenated brain tissue in the treated NPC mice compared to the untreated groups. Therefore, our results suggest that pharmacological inhibition of sEH ameliorates most of the characteristic features of NPC mice, demonstrating that sEH can be considered a potential therapeutic target for this disease.Keywords
All Related Versions
Funding Information
- Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España (SAF2016-77703, PID2019-106285RB)
- Agència de Gestió d'Ajuts Universitaris i de Recerca (2017SGR106)
- Departament d'Empresa i Coneixement, Generalitat de Catalunya (Llavor 00007(2018))
This publication has 47 references indexed in Scilit:
- Lysosomal storage disorders: The cellular impact of lysosomal dysfunctionJournal of Cell Biology, 2012
- Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic IndicationsJournal of Medicinal Chemistry, 2011
- Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Diet-Induced Metabolic Syndrome in RatsExperimental Diabetes Research, 2011
- Niemann‐Pick type C disease: molecular mechanisms and potential therapeutic approachesJournal of Neurochemistry, 2011
- Tau deletion exacerbates the phenotype of Niemann–Pick type C mice and implicates autophagy in pathogenesisHuman Molecular Genetics, 2008
- Niemann-Pick C1-Like 1 Mediates α-Tocopherol TransportMolecular Pharmacology, 2008
- Autophagy in Niemann–Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defectsHuman Molecular Genetics, 2007
- Autophagy and signaling: their role in cell survival and cell deathCell Death & Differentiation, 2005
- Niemann–Pick disease type CClinical Genetics, 2003
- Cholesterol storage and tau pathology in Niemann–Pick type C disease in the brainThe Journal of Pathology, 2003